英夫利西单抗治疗的IBD患者抗SARS-CoV-2抗体反应减弱
本研究比较了英夫利西单抗与维多珠单抗治疗的IBD患者对SARS-CoV-2感染的血清学反应,纳入92家英国医院的6935例患者。结果显示英夫利西单抗组血清阳性率更低(3.4% vs 6.0%),且在确诊感染者中血清转换率更低(48% vs 83%),抗体反应强度更弱,提示抗TNF治疗可能削弱体液免疫应答。
要点
- 英夫利西单抗治疗者SARS-CoV-2血清阳性率低于维多珠单抗治疗者。
- 确诊感染后英夫利西单抗组血清转换率仅48%,显著低于对照组83%。
- 联合免疫调节剂进一步降低血清阳性风险。
核心结论
- 英夫利西单抗与IBD患者对SARS-CoV-2的血清学反应减弱相关,联合免疫调节剂进一步削弱该反应。
研究设计与样本
- 前瞻性队列研究,2020年9月22日至12月23日从92家英国医院招募6935例IBD患者,比较英夫利西单抗组与维多珠单抗参考队列的抗体反应。
主要发现
- 两组症状性和确诊SARS-CoV-2感染率相似。
- 英夫利西单抗组血清阳性率3.4%(161/4685)低于维多珠单抗组6.0%(134/2250),p<0.0001。
- 多变量logistic回归显示英夫利西单抗(vs 维多珠单抗;OR 0.66,95%CI 0.51-0.87,p=0.0027)和免疫调节剂使用(OR 0.70,95%CI 0.53-0.92,p=0.012)与较低血清阳性独立相关。
- 确诊感染者中,英夫利西单抗组血清转换率48%(39/81)低于维多珠单抗组83%(30/36),p=0.00044。
- 英夫利西单抗组抗SARS-CoV-2反应强度中位数0.8切点指数(0.2-5.6)低于维多珠单抗组37.0(15.2-76.1),p<0.0001。
临床怎么用
- 对接受英夫利西单抗治疗的IBD患者应考虑血清学检测和病毒监测,以发现疫苗反应不佳、持续感染和病毒演化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious respiratory infections. We sought to determine whether infliximab-treated patients with IBD have attenuated serological responses to SARS-CoV-2 infections. DESIGN: Antibody responses in participants treated with infliximab were compared with a reference cohort treated with vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody that is not associated with impaired vaccine responses or increased susceptibility to systemic infections. 6935 patients were recruited from 92 UK hospitals between 22 September and 23 December 2020. RESULTS: Rates of symptomatic and proven SARS-CoV-2 infection were similar between groups. Seroprevalence was lower in infliximab-treated than vedolizumab-treated patients (3.4% (161/4685) vs 6.0% (134/2250), p<0.0001). Multivariable logistic regression analyses confirmed that infliximab (vs vedolizumab; OR 0.66 (95% CI 0.51 to 0.87), p=0.0027) and immunomodulator use (OR 0.70 (95% CI 0.53 to 0.92), p=0.012) were independently associated with lower seropositivity. In patients with confirmed SARS-CoV-2 infection, seroconversion was observed in fewer infliximab-treated than vedolizumab-treated patients (48% (39/81) vs 83% (30/36), p=0.00044) and the magnitude of anti-SARS-CoV-2 reactivity was lower (median 0.8 cut-off index (0.2-5.6) vs 37.0 (15.2-76.1), p<0.0001). CONCLUSIONS: Infliximab is associated with attenuated serological responses to SARS-CoV-2 that were further blunted by immunomodulators used as concomitant therapy. Impaired serological responses to SARS-CoV-2 infection might have important implications for global public health policy and individual anti-TNF-treated patients. Serological testing and virus surveillance should be considered to detect suboptimal vaccine responses, persistent infection and viral evolution to inform public health policy. TRIAL REGISTRATION NUMBER: ISRCTN45176516.
引用
- Kennedy NA, Goodhand JR, Bewshea C, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021. PMID: 33753421. doi:10.1136/gutjnl-2021-324388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。